Bionano Genomics

CMS Approves 47% Payment Increase for Optical Genome Mapping in Blood Cancer Diagnostics

- The Centers for Medicare & Medicaid Services increased reimbursement for optical genome mapping in hematologic malignancies by 47%, from $1,263.53 to $1,853.22 for CPT code 81195, effective January 1, 2026. - The clinical diagnostic laboratory test committee voted unanimously 10-0 in favor of the payment increase following a reconsideration request and crosswalk to a higher-paying code. - Bionano Genomics expects the enhanced reimbursement to improve adoption of OGM-based laboratory developed tests as alternatives to traditional cytogenetic methods like karyotyping and FISH. - The company offers three OGM-based diagnostic tests that would benefit from this reimbursement increase, including OGM-Dx HemeOne for blood cancer analysis.